In a small study, an early-stage Parkinson's treatment from partners Prothena and Roche reduced levels of a protein with ties to the memory-destroying disease, sending the former company's shares up about 40%.
Portuguese researchers are developing and testing a smart, portable system to manage Parkinson's disease in real time. The so-called Rempark system has been tested on more than 50 volunteers from Spain, Italy, Ireland and Israel, reports Medical Xpress. Unlike previous studies, these outpatients lived at home and used the device in real-world conditions.
Kees Been has banked the $20 million round needed to move a bold new development program for delaying or preventing Parkinson's toward the clinic. And the veteran biotech CEO at the helm of Lysosomal Therapeutics Inc. is moving forward with a group of high-profile backers in his corner.
Belgian drugmaker UCB has inked a $480 million deal to team up with Neuropore Therapies on some early-stage treatments for Parkinson's disease.
The FDA just approved AbbVie's novel formulation of the standard Parkinson's drugs carbidopa and levodopa, Duopa, which is delivered straight into the patient's small intestine over 16 consecutive hours using an infusion pump and procedurally placed tube.
AbbVie picked up FDA approval for Duopa, an extended-release combination of two standard Parkinson's disease treatments that relies on an external pump.
Genentech has given 23andMe a major boost. The big biotech has reportedly paid $10 million upfront and agreed to $50 million in milestones to access 23andMe's database for target discovery of new drugs for Parkinson's disease.
Investors were thrilled by the Phase IIa clinical trial results of Neuroderm's continuously delivered Parkinson's candidates that are administered via a belt or patch pump, offering patients an alternative to traditional orally delivered levodopa, which is notorious for its fluctuating concentrations in the blood.
Animal studies typically don't do much for a biotech's stock price. Findings can be hard to replicate, animal models often don't translate well to human studies and hopeful signs seen at the preclinical stage can vanish in an instant--particularly in tough fields like neurodegeneration.
Rebounding from a disappointing IPO, Israel's NeuroDerm watched its shares more than double on promising results from a small study of its Parkinson's disease treatments.